



- Le rapprochement cellulaire
- La synapse immunologique (cours SGD)
- Les molécules de l'activation
  - TCR: CMH-Ag + Co-récepteur CD4, CD8
  - Mol co-stimulation
  - Cytokines

 Aspects quantitatifs et qualitatifs de l'activation

- Affinité de l'interaction
- Avidité de l'interaction
- Dynamique des interactions moléculaires
- et ses conséquences sur le développement de la réponse immunitaire
  - Détermine le programme de différenciation T

## Activation lymphocytaire T





Bertrand Bellier UPMC CNRS UMR7211 Immunologie-Immunopathologie-immunothérapie Pitié-Salpêtrière - Paris - France bertrand.bellier@upmc.fr

Activation lymphocytaire T



 Interactions moléculaires de la reconnaissance antigénique pour l'activation T

Dynamique des interactions

 Conséquences des interactions sur la différenciation T Plan



Bases moléculaires de la reconnaissance antigénique

Influence des paramètres de l'interaction TCR/CMH-Ag





## Reconnaissance antigénique

Interactions TCR / MHC-Ag:

< Vert = MHC Rouge = TCR Jaune = peptide antigénique



Aff nité TCR /CMH-Ag: KD ~1-50 ffM. ff

Significativement plus faible que les autres interactions protéines-protéines aux conséquences biologiquesff





$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Table 1. Bind	ding measurements for w	ild-type T-cell receptor	5		r∿ <sub>D</sub> 1-50 uN	Ра	rame
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	TCR	Peptide/MHC	k <sub>on</sub> (per м second	$k_{\rm off}$ (per second)	t <sub>1/2</sub> (seconds)	K <sub>D</sub> (μs)	Activity	Reference
P14         g3MD <sup>b</sup> 400 000         9.975         0.7         2.4         Agenist         4           CC         p3Cult <sup>a</sup> 8300         0.027         2.7         3.4         Agenist         5           2C         Q2Cult <sup>a</sup> 6300         0.025         26.8         3.9         Agenist         5           2C         Q1ML <sup>a</sup> 61000         0.035         2.0         5.7         Agenist         5           OT-1         OVA/C4)/L <sup>b</sup> 900         0.022         31.5         5.9         Agenist         5           OT-1         OVA/C4/L <sup>b</sup> 16 000         0.28         2.4         18         Weak agenist         5           C26         S1Y/K <sup>b</sup> 2000         0.464         1.5         2.74         Agenist         6           2C         d58/D <sup>b</sup> 2200         0.185         3.7         84.1         Areagenist         6           2C         d58/D <sup>b</sup> 2200         0.11         6.1         1.9         Agenist         6           AfMII 1.2         D105M <sup>b</sup> 3000         0.16         4.2         2.2         Agenist         6           Af         TaxHIA.A2<	CT26	AH1(A5)/L <sup>d</sup>	58 000	0-11	6-3	1.9	Agonist	<u>э</u>
2C $p2Cu/L^*$ 8300 $0.027$ $257$ $3.5$ Appnist $57$ C2         Q1SU <sup>4</sup> $6350$ $0.027$ $257$ $3.54$ Appnist $57$ CT26         AH1/L <sup>4</sup> $6100$ $0.355$ $2.0$ $57$ Agonist $57$ OT-1         OVAR <sup>b</sup> $3720$ $0.022$ $31.5$ $59$ Agonist $57$ CT26         AH1(A7)/L <sup>6</sup> $16000$ $0.28$ $2.4$ $18$ Weak agonist $7$ C2         ST/R <sup>A</sup> $22000$ $0.4644$ $1.5$ $27.4$ Agonist $8$ C126         AH1(A7)/L <sup>6</sup> $6610$ $0.538$ $1.2$ $81.4$ Matagonist $8$ C2         dEVR <sup>6</sup> $2200$ $0.185$ $57$ $84.1$ Antagonist $8$ G1         HVmps/LVHLA-A2 $49000$ $0.11$ $61$ $1.9$ Agonist $10$ G10         HVmps/LVHLA-A2 $39000$ $0.66$ $74$ $3$	P14	gp33/D <sup>b</sup>	400 000	0.975	0-7	2-4	Agonist	4
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2C	p2Ca/L <sup>d</sup>	8300	0-027	25-7	3.3	Agonist	5
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2C	QL9/Ld	6350	0-025	26-8	3.9	Agonist	2
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	CT26	AH1/L <sup>d</sup>	61 000	0-35	2.0	5.7	Agonist	3
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	OT-1	OVA/K <sup>b</sup>	3720	0-022	31-5	5.9	Agonist	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	OT-1	OVA(G4)/K <sup>b</sup>	900	0-009	77	10	Weak agonist	2
2C         SY/K*         22 000         0-664         1-5         27-4         Agonist         4           AHIII 12.2         p1058/D*         6610         0-538         1-2         81-4         Weak agonist         5           AHIII 12.2         p1058/D*         6210         0-185         3-7         84-4         Weak agonist         5           B7         Tas/HA-A2         96 000         0-13         5-2         1-2         Agonist         16           A6         Tas/HA-A2         49 000         0-11         6-1         1-9         Agonist         16           G10         HV <sub>PS</sub> SI/HLA-A2         30 000         0-66         11-2         2.2         Agonist         16           G18         Fla/HLA-A2         31 000         0-16         4-2         5-2         Agonist         16           G10         HV <sub>PS</sub> SI/HLA-A2         31 000         0-16         4-2         5-2         Agonist         16           g1000         g100/HLA-A2         31 000         0-16         4-2         5-2         Agonist         16           g1014         g100/HLA-A2         31 000         0-12         5-2         17         12.5         Agonist         16 </td <td>CT26</td> <td>AH1(A7)/Ld</td> <td>16 000</td> <td>0-28</td> <td>2-4</td> <td>18</td> <td>Weak agonist</td> <td></td>	CT26	AH1(A7)/Ld	16 000	0-28	2-4	18	Weak agonist	
AHIII 12.2         p10580 <sup>b</sup> 6610         0.538         1-2         81-4         Wrack agonist         *           2C         dEV8R <sup>b</sup> 2200         0.185         3.7         84-1         Antaconist         *           3F         Tax/HA-A2         96 000         0.13         5.2         1.2         Agonist         *           A6         Tax/HA-A2         49 000         0.11         6-1         1.9         Agonist         *           G10         HVmpSLVHLA-A2         39 000         0.06         1.2         2.2         Agonist         *           GRB         Fu/HA-A2         31 000         0.16         4.2         5.2         .         *           G10         HVmpSLVHLA-A2         31 000         0.16         4.2         5.2         .         *           G10         HVmpSLVHLA-A2         31 000         0.44         1.5         6.3         .         .           G10         HVmpSLVHLA-A2         31 000         0.23         2.9         .         .         .         .           G113         FLR(A)HLA-B8         5 800         0.42         .7         .         .         .         .         .	2C	SIY/K <sup>b</sup>	22 000	0-464	1.5	27-4	Agonist	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	AHIII 12.2	p1058/D <sup>b</sup>	6610	0-538	1.2	81-4	Weak agonist	
B7         Tat/H1A-A2         96 000         0-13         5-2         1-2         Agonist         96           A6         Tat/H1A-A2         49 000         0-11         6-1         1-9         Agonist         96           G10         HIV <sub>pp</sub> 5LY/H1A-A2         330 000         0-066         11-2         2-2         Agonist         97           GR8         Hu/H1-A27         99 000         0-09         7-4         3         72           GR0         HIV <sub>pp</sub> 5LY/H1A-A2         31 000         0-16         4-2         5-2         Agonist         16           G10         HIV <sub>pp</sub> 5LY/H1A-A2         31 000         0-16         4-2         5-2         Agonist         16           G10         HIV <sub>pp</sub> 5LY/H1A-A2         30 000         0-23         2.9         7         12         Agonist         16           g100         g100         0-16         0-25         2.3         11.3         Agonist         16           g111         21 0000         0-128         6-4         32         Agonist         16           AMS         EW/H1A-A2         3000         0-128         6-4         32         Agonist         16           LC13         FLR(HH	2C	dEV8/K <sup>b</sup>	2200	0-185	3-7	84-1	Antagonist	3
A6         Tar/HLA-A2         49 000         0-11         6-1         1-9         Agonist         #           GI0         HV <sub>xy</sub> SLY/HLA-A2         330 000         0-09         7-4         3         -	B7	Tax/HLA-A2	96 000	0-13	5-2	1.2	Agonist	10
G10         HIV <sub>p</sub> SI/HLA-K2         39 000         0.06         11-2         2.2         Agonist         1           GRB         Pla/HLA-K27         39 000         0.09         7.4         3         -	A6	Tax/HLA-A2	49 000	0-11	6-1	1.9	Agonist	340
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	G10	HIV SLY/HLA-A2	330 000	0-05	11-2	2.2	Agonist	11
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	GRB	Flu/HLA-B27	39 000	0-09	7-4	3		14
G10         HV model H1 model         Product H1 model         Product H1 model         Product H1 model         Hermitian         He	JM22	Flu/HLA-A2	31 000	0-16	4-2	5-2		13
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	G10	HIVSLF/HLA-A2	340 000	0-16	4-2	5-2	Agonist	81
gp100         gp100/HLA-A2         31 000         0-23         2-9         7         12           AHIII 12.2         p1609/HLA-A2         32 000         0-295         2.3         11.3         Agoniat         9           LC13         FLR(A)/HLA-82         35 800         0-42         1.7         12.5         Agoniat         15           AM3         EW/HLA-A2         7300         0-21         3-2         28         12         12           IC4         NY-ESO-HILA-A2         4000         0-128         6-4         32         Agoniat         16           TEL         tel/HLA-A2         3500         0-14         4-8         40         12         Intanois         13           TC11         FLR(F)HLA-88         5620         0-35         2.0         132         Antagonist         13           T2.10         MBPI-11[47]/1-4"         37 200         0-219         3-1         5-9         Agonist         13           J3.2         Hb/L-4"         5557         0-66         10-8         12         Agonist         13           J3.4         MPC-14"8"         633         0-057         17.7         90         Agonist         12           AHL	CMV	pp65/HLA-A2	70 000	0-44	1-5	6-3		14
AHIII 12.2         p1649/HLA-A2         26 200         0.295         2.3         11.3         Agonist         9           LC13         FLR(A)/HLA-B8         35 800         0-42         1.7         12.5         Agonist         15           MAS         E8/V/HLA-A2         7300         0-21         3.2         2.8         12           164         NY-ESO-1/HLA-A2         40 000         0-128         6-4         3.2         Agonist         16           1C13         FLR(F)/HLA-A2         3500         0-14         4.8         40         12           1C34         RH[Y-HIA-A2         3500         0-16         4.8         40         13           1C13         FLR[F)/HLA-A2         3500         0-14         4.8         40         13           1C13         FLR[F)/HLA-A2         3500         0-16         12         Agonist         15           312         Hbf-8 <sup>±</sup> 5557         0-06         10.8         12         Agonist         16           1934.4         MBP1-11[4Y]/1-8 <sup>±</sup> 5130         0-16         4-2         31         Weak agonist         17           284         MCC/1-E <sup>±</sup> 633         0-057         11-7	gp100	gp100/HLA-A2	31 000	0-23	2.9	7		12
LC13         FLR(A)/HLA-B8         35 800         0-42         1-7         12-5         Agonist         13           AM3         EBV/HLA-A24         7300         0-21         3-2         28         12         12           IG4         NY-ESO-1/HLA-A24         40000         0-128         6-4         32         Agonist         16           TEL         tel/HLA-A2         3500         0-14         4-8         40         12           IC13         FLR(P)HLA-82         3500         0-14         4-8         40         12           IC13         FLR(P)HLA-82         3500         0-14         4-8         40         12         Antagonist         15           IC13         FLR(P)HLA-82         2620         0-35         2-0         12         Antagonist         15           J21         MBP1-11(P)/I-A*         37200         0-219         5-1         5-9         Agonist         16           J3L2         Hb/I-E*         5557         0-06         10-8         12         Agonist         16           J84.4         MCC/L-E*         633         0-057         11-7         90         Agonist         2           AHL23         C-HSPHLA-DB4 <td>AHIII 12.2</td> <td>p1049/HLA-A2</td> <td>26 200</td> <td>0-295</td> <td>2.3</td> <td>11-3</td> <td>Agonist</td> <td></td>	AHIII 12.2	p1049/HLA-A2	26 200	0-295	2.3	11-3	Agonist	
AM3         EBW/HLA-A24         700         0-21         5-2         28         12           IG4         NY-ESO-1/RLA-A2         40 000         0-128         6-4         32         Agonist         16           IE1         tel/HLA-A2         3500         0-14         4-8         40         12           LC13         FLR(F)/HLA-B8         2650         0-55         2.0         122         Antagonist         15           JC10         BR/1-1(§Y)/HA-B8         2650         0-55         2.0         12.2         Antagonist         17           JS12         Hdr-E*         5557         0-06         10-8         12         Agonist         17           JS14         Hdr-E*         5557         0-06         10-8         12         Kweak agonist         17           JS44         MCC/L*         633         0-057         1.7         90         Agonist         12           AHU3         M-HSPHILA-DR4         4000         0-16         4-2         36         12           AHU2         C-HSPHLA-DR4         4000         0-16         4-2         36         12	LC13	FLR(A)/HLA-B8	35 800	0-42	1.7	12-5	Agonist	15
IG4         NY-ESO-I/HLA-A2         40 000         0-128         6-4         32         Agonist         15           TEL         tel/HLA-A2         3500         0-14         4.8         40         16           TEL         tel/HLA-A2         3500         0-14         4.8         40         15           LC13         FLR[r]/HLA-B2         2620         0-55         2.0         12.2         Antagonist         15           J172.10         MBP1-11[4Y]/LA"         37 200         0-219         3-1         5-9         Agonist         17           J12         Hbf-8 <sup>h</sup> 5557         0-06         10.8         12         Agonist         17           J14         MBP1-11[4Y]/LA"         5130         0-16         4-2         31         Weak agonist         17           J284         MCC/L <sup>E</sup> 633         0057         11.7         90         Agonist         2           AltL32         C-HSPHLA-DB4         400         0-12         5-6         30         2         2           AltL32         C-HSPHLA-DB4         400         0-16         4-2         36         12	AM3	EBV/HLA-A24	7300	0-21	3-2	28		12
TEL         tel/HLA-A2         3500         0-14         4-8         40         12           LC13         FLR(F)HLA-A2         3500         0-14         4-8         40         13           LC13         FLR(F)HLA-A2         3500         0-55         2-0         132         Antagonist         13           J172.10         MBPI-11[47]/1-A"         37 200         0-219         3-1         5-9         Agonist         13           J3.2         Hb/L-E"         5557         0-06         10-8         12         Agonist         13           J954.4         MPI-11[47]/1-A"         5130         0-16         4-2         31         Weak agonist         12           ZB4         MCC/L-E"         633         0-057         1.7         90         Agonist         2           AHL23         C-HSPHLA-DB4         400         0-12         5-6         30         12           AHL23         C-HSPHLA-DB4         400         0-16         4-2         36         12	1G4	NY-ESO-1/HLA-A2	40 000	0-128	6-4	32	Agonist	16
LC13         FLR(F)/HLA-B8         2620         0.35         2.0         132         Antagonist         13           172.10         MBP1-11(47)/LA*         37 200         0.219         3.1         5.9         Agonist         17           13.2         Hb/F-E*         5557         0.06         10.8         12         Agonist         18           1954.4         MBP1-11(47)/L-A*         5130         0-16         4-2         31         Weak agonist         17           2B4         MCC/L-E*         633         0.057         1.17         90         Agonist         12           MAW 13         M-HSP/HLA-DB8         4000         0-12         5-6         30         12           AHL23         C-HSP/HLA-DB4         400         0-16         4-2         36         12	TEL	tel/HLA-A2	3500	0-14	4-8	40		12
J72.10         MBP1-11[4Y]/1-A*         J7 200         0-219         5-1         5-9         Agonist         17           3.1.2         Hb/1-E <sup>h</sup> 5557         0.06         1.08         1.2         Agonist         18           954.4         MBP1-11[4Y]/1-A*         5150         0.16         4-2         3.1         Weak agonist         17           2B4         MCC/L-E*         633         0.057         11.7         90         Agonist         2           AMV 13         M-HSPHLA-DB4         400         0.12         5-6         30         12           AHL23         C-HSPHLA-DB4         400         0.16         4-2         36         12	LC13	FLR(F)/HLA-B8	2620	0-35	2.0	132	Antagonist	15
3.1.2         Hb/l-E <sup>k</sup> 5557         0.06         10.8         12         Agonist         18           1954.4         MRPI-11[47]/l-A <sup>*</sup> 5130         0-16         4-2         31         Weak agonist         17           2B4         MCC/L'E <sup>k</sup> 633         0.057         11-7         90         Agonist         2           AMU 13         M-HSP/HLA-DR3         4000         0-12         5-6         30         12           AHL23         C-HSP/HLA-DR4         4000         0-16         4-2         36         12	172.10	MBP1-11[4Y]/I-A"	37 200	0-219	3-1	3.9	Agonist	17
1934.4         MBP1-11[4Y]/1-A*         5130         0-16         4-2         31         Weak agonist         17           2B4         MCC/1-E*         633         0.057         11-7         90         Agonist         2           MW 13         M-HSPHLA-DB4         400         0-12         5-6         30         12           AHL23         C-HSPHLA-DB4         400         0-16         4-2         36         12	3.1.2	Hb/I-E <sup>k</sup>	5557	0.06	10-8	12	Agonist	18
2B4         MCC/LE <sup>b</sup> 633         0.057         11-7         90         Agonist         2           MAW 13         M-HSP/HLA-DR3         4000         0-12         5-6         30         12           AHL23         C-HSP/HLA-DR4         400         0-16         4-2         36         12           J13         M-BPUH L-DR3         200         0.17         3.0         81         12	1934.4	MBP1-11[4Y]/I-A9	5130	0-16	4-2	31	Weak agonist	17
MAW 13 M-HSP/HLA-DR3 4000 0-12 5-6 30 12 AHL23 C-HSP/HLA-DR4 4400 0-16 4-2 36 12 JUS MERUH A DR3 200 0-17 3.0 81 12	2B4	MCC/I-E <sup>k</sup>	633	0-057	11-7	90	Agonist	2
AH1.23 C-HSP/HLA-DR4 4400 0-16 4-2 36 <sup>12</sup>	MAW 13	M-HSP/HLA-DR3	4000	0-12	5-6	30		12
1412 MRP/HTA DP3 2100 0.17 10 91 12	AH1.23	C-HSP/HLA-DR4	4400	0-16	4-2	36		12
1014 2107/11/0/1/04 4107 217 229 01	1A12	MBP/HLA-DR2	2100	0-17	3.9	81		12

K2n equilibrium binding constant; k\_on, association rate; k\_oth dissociation rate; MHC, major histocompatibility complex; r1/2n half-life of the interaction; TCR, T-cell receptor

Measurements performed at 25°.

Table 1

CD8<sup>+</sup> T Cell Activation Is Governed by TCR-Peptide/MHC Affinity, Not Dissociation Rate1

Shaomin Tian,\* Robert Maile,\*' Edward J. Collins,\*1 and Jeffrey A. Frelinger2\*

#### CD8+ TCR-transgénique (P14 = TCR Va2 Vb8) Ag = GP33-41 / LCMV Or GP33-41 mutants (C9L, K1MC9M)β

tion Sile	Segurner	Pepildr Mature		
one	KAVYINFATC	gp33		
	KAVYINFATC	KIA, KID, KIE, KIF, KIL, KIN, KIR, KIS, KIV, KIW, KIY		
	KAVYINFADC	A2D, A2E, A2F, A2G, A2K, A2L, A2N, A2R, A2S, A2T, A2V, A2W, A2Y		
	KANYNERADC	V3A, V3D, V3E, V3F, V3G, V3K, V3L, V3N, V3R, V3S, V3T, V3W, V3Y		
	KAVYNEADC	Y4A, Y4C		
6	KAVTNFATC	194		
	KAVTNFATC	C9A, C9D, C9E, C9F, C9K, C9L, C9M, C9N, C9K, C9S, C9V, C9W		
1.9%	KAVUNEADC	KLACHM, KIMCHM, KISCHM		
1. 210	KAUTINEATC	VILCOM		
6.99	KAVYINFACC	Y4FC9M, Y4SC9M		

Table II. Effects of gp33 variants on T cell systematicity, IFN-y production, and TCR binding

Peptide	SC <sub>20</sub> <sup>175</sup> (aM7	$\mathrm{BC}_{\mathrm{B1}} \cong (\rho M)^4$	$K_{cc}$ ( $\mu M$ )"	36 (icsl - mol - ')*	$k_{\rm m}  (\times 10^9  {\rm M}^{-1} \cdot {\rm s}^{-1})^{\circ}$	Aug (8-17	4.12 (4)
gp33	$16.8 \pm 16.8$	0.06 ± 0.01	12.2 = 2.2	-6.79	$1.33 \pm 0.27$	$1.35 \pm 0.68$	0.51
CSF	$0.53 \pm 0.36$	$0.56 \pm 0.44$	$9.4 \pm 0.5$	-6.95	1.19 ± 0.01	$1.15 \pm 0.01$	0.60
<ul> <li>C9L</li> </ul>	$1.36 \pm 2.1$	$0.47 \pm 0.63$	8.6 = 0.2	-7.00	$0.99 \pm 0.02$	$0.79 \pm 0.02$	0.88
CSM	1.59 = 2.67	0.92 = 0.39	$9.1 \pm 1.4$	-6.96	$1.42 \pm 0.54$	$1.2 \pm 0.46$	0.58
C9V	$3.20 \pm 5.60$	$1.23 \pm 0.27$	$10.8 \pm 0.3$	-6.85	1.16 ± 0.03	$1.25 \pm 0.03$	0.55
KIMC9M	8.58 ± 5.27	$0.13 \pm 0.09$	$74.5 \pm 13.6$	-5.70	0.33 ± 0.08	$3.53 \pm 0.7$	0.20
KIR	49.0 = 22.0	$7.96 \pm 1.06$	81.6 = 10.6	-5.65	$1.31 \pm 0.47$	$10.6 \pm 3.5$	0.065
K1SC9M	>50.000	$28.0 \pm 4.55$	267	-4.94	0.01	0.26*	2.67
VILCIM	>50,000	112.8 ± 75.5	$264 \pm 103^{o}$	-4.94	ND <sup>#</sup>	ND <sup>4</sup>	NDF
¥4A	8.870 = 5.550	$11.57 \pm 7.47$	63.0 = 14.3	-5.8	$0.38 \pm 0.07$	$2.2 \pm 0.57$	0.32
Y4FC9M	>50.000	38.55 ± 22.03	681*	-4.38	ND <sup>*</sup>	NDf	ND*
V45C9M	> \$0.000	261.1 ± 157.5	\$30*	-4.53	ND*	ND <sup>e</sup>	ND*

peptide that gives \$0% maximum CTL activity as de lease assay. The values represent the mean 2 is the objective concentration of neurile that induces \$2% of the maximum answer of DN 5 to deserviced by ILHS. The values reservent the maximum answer of DN 5 to deserviced by ILHS.

ely-star SPR data with software Scrabber. The values represent the near 2. SD of two is these experiments. -RT is  $R_{cc}$  where RT at 2572 is -0.5 kod - meV<sup>-1</sup>. it is SPR data with behave CLAMP RAT The values represent the mean 2. SD of two to three experiments. is of pMRC those PF4 TOR. Determined by  $t_{eff} = \ln 2k_{db}$ .





Log [Peptide] ( M)

FIGURE 5. Via groups (pars) IGURE 5. Via groups gp30 and APA, variably sensitize P14 T cells w kill target cells. EL4 cells indeed with "Cr and pulsed with peridear at mirror concentrations were incidented with activated pelseoprese from P14 UCR transgenic mice (ELT ratio -3) for 4 h. Specific lysis of EL4 cells so measured by "Cr traines. Theremate HT0K1A1 periods (LGSBN EQV3) was used as targative centric. Data are shown as mean  $\pm$  30 (n =), and are representative of first as the independent experiment. Using Graphical Prism, data were B1 into signalida dose response mode to ob-in EQ.<sup>(3)</sup> values (down to Table ID1 (Diffing curves an to shown).



CTL

### Importance de l'affinité du TCR pour l'activation lymphocytaire (2)

IFNa



IL-2 Gen



.....

peptide (TAFNEGLK) showing in blue the location of the four surface-exposed residues P2(T), P3(A), P5(N), and P8(L). B, 3.L2 M1 (unmutated CDRs) and <u>three higher aff nity mutants</u> (M4, M14, and M15) with the location of their CDR mutations and respective KD, t1/2, kon, and koff values. The CDRbeta1,2,3 and CDR{alpha}1,2,3 are designated from left to right by circles: {circ}, indicate that the CDR is not mutated; •, indicate mutations in the CDRbeta or CDR{alpha}, respectively. The amino acid mutations in these regions are the same as previously published (43).ff



## II. Activation T : un système dynamique



## Stimulation réitérative du lymphocyte: « kinetic proofreading » model

- Activation du lymphocyte T si interaction TCR/ CMH-Ag suffisante (seuil d'activation)
- Interactions :
  - Force d'interaction (Affinité)
  - Temps d'interaction (Koff)
  - Nombre d'interactions (x n; Avidité)
- Activation progressive des molécules de signalisation (phosphorylation) : seuil d'activation
- Seuil critique pour initier une activation fonctionnelle
- Si interaction insuffisante (k<sub>off</sub> faible, dissociation du complexe TCR/CMH-Ag) avant initiation de l'activation: les groupements phosphates seront éliminés par les phosphatases cellulaires (McKeithan 1995)







Seuil d'activation: T naïf vs T mémoire



Seuil d'activation: T naïf vs T mémoire



Curtsinger, JI 1998





## Serial triggering of many T-cell receptors by a few peptide-MHC complexes Valitutti, Nature 1995



T cells conjugated with peptide-pulsed APCs undergo an antigen-dependent downregulation of the TCR/CD3 complex.ff



#### Serial triggering of many T-cell receptors by a few peptide-MHC complexes Valitutti. Nature 1995



we measured at different antigen concentrations the number of complexes per APC and the number of TCRs downregulated after T-APC interaction. In one series of experiments, EBV-B cells were pulsed with different concentrations of **125 I-labelled peptide** and the number of peptide-DR complexes per cell was calculated at each peptide concentration Figure 3(a). In parallel experiments, the fraction of TCRs downregulated by APCs pulsed in the same conditions was measured Figure 3(b). From comparison of the two curves it is estimated that APCs pulsed with high peptide concentrations (20 micromolar) display approximately 7,500 complexes and induce downregulation of 93 percent of TCRs. Strikingly, APCs pulsed with a low peptide concentration (50 nM) display only approximately 100 peptide-DR complexes, yet they downregulate 62 percent of TCRs. The relationship between the number of peptide-DR complexes per APC and the number of TCRs downregulated per T cell is shown in Figure 3(c). This plot clearly shows that each peptide-DR complex must engage a large number of TCRs in successive rounds. This effect is dramatic at low complex density, where approximately 100 complexes can trigger up to 18,000 TCRs. but is less marked at high complex density, indicating that a single peptide-DR must be able to trigger 180 TCRs in successive rounds. This figure may increase at lower complex density and could be an underestimate as it is unlikely that all complexes present on an APC may be available to the responding T cell.



### Nombre d'interactions TCR/CMH-Ag: aspects moéculaires

- Minimum 1 à 50 complexes CMH-Ag sur APC pour activer LyT
- Engagement multiple des TCR pour un complexe CMH-Ag
   N= 200 contacts répétitifs (Valitutti 1995)



- Temps de contact cellulaire requis ? (Long / Court)
  - Temps de contact TCR/CMH-Ag limité pour assurer des engagements répétés des TCR



### Influence de la « demi-vie » de contact

### L.J. Carreño et al. / Immunobiology 211 (2006) 47-64



Fig. 2. T cell activation depends on TCR/pMHC interaction half-life and pMHC density. (A) When T cells interact with cognate pMHC at low density on the APC, efficient activation takes place within an optimal range of TCR/pMHC interaction half-life. Interactions with short half-lifes cannot complete necessary intracellular signals for T cell activation, due to impairment on TCR kinetic proofreading. TCR/pMHC interactions with excessively long half-lives impair T cell activation due to TCR serial engagement blocked. At low pMHC density, the pitor of T cell activation serues TCR/pMHC half-life results in a Gaussian distribution, in which only pMHCs that interact with intermediate half-lives with the TCR behave as agonits (Kalergis et al., 2001; Cocomb et al., 2002). (B) When T cells interact wito cognate pMHC at half-lives (MHC, TCR cell activation can take place when the half-life of the TCR/pMHC cleatisty, the pitor of T cell activation versus TCR/pMHC half-life results in a Gaussian distribution, in which pMHCs that interact with intermediate or high, because strail engagement toologare applies (Gonzake et al., 2003). If Migh PMHC density, the pitor of T cell activation versus TCR/pMHC half-life results in a signoid distribution, in which pMHCs that interact with intermediate and long half-lives with the TCR behave as agonists.

### Nombre d'engagements



LFA-1

Хn



### Rôle des molécules adaptatrices

- CD4: CMH-II
- CD8: CMH-I
- Transduction du signal : renforcement des voies de signalisation







The  $\beta\beta$ -negative T cell hybridoma 58/was cotransfected with the 2C wt  $\beta$  chain gene and one of five different  $\beta$  chain genes from 2C and the mutants m6\beta m13 $\beta$  m33 $\beta$  and m67 $\beta$ . Stable transfectants that expressed similar levels of TCR were identified based on their staining with anti-V $\beta$  antibody KJ16

Sensitization Doses of Various QL9 Position 5 Variant PeptidesIL-2 production by transfectants stimulated with various peptides was measured as lescribed in the Experimental rocedures. The amount of peptide that ielded 50% of the maximum IL-2 alease (SD50) was calculated by linear agression of IL-2 curves (see Figure S1 thttp://www.immunity.com.eatLinist.ft)

<u>Evidence information are indicating and an are not appear</u> as the symbol.

>> Aide à l'activation des clones T de faible affinité



Rôle des molécules adaptatrices : CD8

Relationship of Peptide Activity and TCR:peptMHC AffinitySDB values of values paylates were platted to negative stress of the analysis of the corresponding TCR:peptMHC interaction (TLLL-1). In order to include values from the Ld and Kb systems, SD50 values from the two different antigen-presenting cell systems (T2-Ld and T2-Kb) are shown on the two Y-axes. The points represent data derived from CD8-negative transfectants (blue cricels) and CD86/Bransfectants (red squares) of the corresponding TCR transfectant. The correspond TCR/pepMHC interactions are shown at the bottom of the figure. The range of KD values that correspond to affinities measured for k nown TCR:syngeneic MHC interactions from in vivo CTLs are shown. This range falls exclusively in the CD8-dependent category, as determined by TCR-transfection studies (not necessarily anti-CD8 antibody inhibition studies).

Holler D , Imm 2003



### Rôle des molécules de costimulation:





### Mécanismes possibles de la tolérance périphérique



### Mol de costimulation et synapse





### DC maturation is required for effective clustering and SMAC formation at the DC-T cell contact siteß

De Efficient clustering in niver Tells requires Confractingues guita SIALC Jornitation of CD3, LFA-1, LAT, and tublin in Tells forming conjugates with immature DC subject Tells requires DC maturation. Confocal images showing the distribution of CD3, LFA-1, LAT, and tublin in Tells forming conjugates with immature DC subject panels) or mature DCs (lower panels) is shown for each mature, For each immunofluorescent image (right panels). A DC image showing the distribution of CD3, LFA-1, LAT, and tublin in tells forming conjugates showing the distribution of CD3, LFA-1, LAT, and tublin in tells forming conjugates showing the distribution of CD3, LFA-1, LAT, and tublin and the CS, and clustered in conjugates formed with immature DCs. Support, but Tells forming arrow) is reoriented to ward the AFC is in conjugates with immature DCs. Support, but Tells forming or noisy arrow is reoriented to ward the AFC is in conjugates showing the distribution of the proportion of conjugates showing of CD3, LFA-1, LAT, and tublin at the site of contact. Conjugates with animature DCs. Materials and Methods) and Expressed as a percentage of the total number of conjugates analyzed (percent clustering). Number of conjugates quantified is so follows: CD3, immature, n = 276; mature, n = 237; and tublin in immature, n = 232, and tublin in immature, n = 234, for the Support of Support in the site of contact conjugates analyzed (percent clustering). Number of conjugates quantified is so follows: CD3, immature, n = 347; LFA-1, immature, n = 232, and tublin in immature, n = 230; for tubling in terms of the protein section of the site of the



# Nécessité d'un engagement prolongé de CD80/CD86

Liwski, Imm Letters 2006



To investigate the functional effects of CD80/CD86 blockade on naive CD4+ T cell activation, freshly isolated CD4+ T cells from OVA-TCR transgent D011.10 mice [27] were labeled with CFSE and cultured with OVA-peptide pulsed, mature DC in the absence or presence of CD80 and CD86 specific mAbs.ff



We demonstrated that DC mediated CD80/CD86 costimulation controls the magnitude of the naive T cell proliferative response by regulating both responder frequency as well as proliferative capacity.ff

ime of Ab Add

Our data revealed that blocking CD80/CD86 signaling up to 6 h after conjugate formation resulted in a significant decrease in both the number of naive T cells entering the proliferative cycle and the number of daughter cells generated by each cell.ff







Duration of contacts (sec)

## Mol costimulation et dynamique de l'interaction

 $\label{eq:constraint} Federica Benvenuti, JI 2004; Dendritic Cell Maturation Controls Adhesion, Synapse Formation, and the Duration of the Interactions with Naive T Lymphocytes$ 



Proliferation of naive T cells stimulated by **immature or mature DCs**. Immature or mature D1 pulsed with different doses of peptide were cocultured for 5 days with CFSE-loaded naive T lymphocytes (15 ratio). A, Representative do tolb toprofile showing the loss of CFSE and the up-regulation of CD44 induced by immature (*upper row*) or mature (*lower row*) DCs loaded with different peptide doses at day 3. A. Britsogram profile of CFSE staining on naive T cells stimulated with immature (*upper row*) or mature (*middle row*) DCs loaded with 1 nM H-Y and mature DCs loaded with 0.1 mM peptide (*lower row*) at days 2-5 of the coculture. C, Quantification of the absolute number of CD+1 + T cells at the different days of coculture for immature () and mature () DCs loaded with 1 nM peptide (T cells at day 0 = 7 x 104). One representative of three experiments is shown filtered.



## III. Conséquence des paramètres d'interactions T sur la réponse immunitaire

1. Mise en place de la réponse primaire

2. Différenciation T



### Paramètres de l'activation T





## Stabilité du complexe CMH-peptide détermine la sélection clonale T

Peptide-MHC Class II Complex Stability Governs CD4 T Cell **Clonal Selection** 

Christina K. Baumgartner, Andrea Ferrante, Mika Nagaoka, Jack Gorski, and Laurent P. Malherh



nMHCII stability

To determine the clonal composition of the responding T cells

induced by peptides with varying binding half-lives with MHCII

molecules, we sorted single Ag-specific CD4 T cells (Val1+VB3+







**Clonal Selection** 

### Stabilité du complexe CMH-peptide détermine la sélection clonale T



### Affinité & Dégénérescence de la reconnaissance TCR

The Study of High-Aff nity TCRs Reveals Duality in T Cell Recognition of Antigen: Specificity and Degeneracyff D Donermeyer et al; Journal of Immunology, 2006, ff



Degeneracy in the recognition of Hb correlates with increased aff nity. CD4+ T cell hybridomas expressing 3.L2, M4, M14, and M15 TCRs were stimulated with the indicated peptide concentrations of Hb or APLs of Hb at the P8 (75) position using CH27 as APC. The APLs are designated as described in Fig. 2. The level of T cell stimulation was determined using a bioassay for IL-2. The cpm values of [3H]TdR incorporation into CTLL-2 cells represent the mean  $\pm$  SD of triplicate values of a representative experiment (n > 3).ff



Christina K. Baumgartner, Andrea Ferrante, Mika Nagaoka, Jack Gorski, and Laurent P. Malherbe  $\Box V_{\alpha} 11^{+} V_{\beta} 3^{+} CD44^{hi} CD62L^{lo}$ cells V<sub>a</sub>11<sup>+</sup> pMHCIITet<sup>+</sup> CD44<sup>hi</sup> CD62L<sup>l0</sup> 6<sup>10</sup> <u>छ</u> 1 MCC95A PCC88-104 MCC88-103 PCC103K PCC88-104 MCC95/  $1.0 \pm 0.8$ Tet

Peptide-MHC Class II Complex Stability Governs CD4 T Cell



>>Preferential accumulation of high-affinity CD4 T cells with lowstability peptides





### Importance des paramètres d'activation : Génération des T mémoire



#### Masopust Curr Op Imm 2004

The Goldilocks model of effector and memory CD8+ T-cell development. The first 24 hours following antigenic stimulation elicits a program of expansion and differentiation that continues among daughter cells after removal of antigen. Too little' stimulation, meaning insufficient antigen concentration or duration, leads to limited CD4 T-cell expansion, poor memory development and attrition. Chronic antigen exposure may cause 'too much' stimulation, leading to a progressive loss in the ability to secrete cytokines and the eventual deletion of antigen-specific CD8+T cells. Optimum memory development is favored when conditions are 'just right'; that is, when CD8+ T cells are stimulated by a sufficient concentration of antigen for a sufficient, but not excessive period of time. Several variables, such To the set is an under of your subset of the set of the maintenance



# Importance de la stimulation antigénique initiale:

- Susan M. Kaech & Rafi Ahmed Nature Immunology 2001 ; Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells
- Models for proliferation and differentiation of naïve CD8+ T cells.(a) CD8+ T cell proliferation is dependent on repeated encounters with antigen. Each cell that is stimulated by antigen divides and progressively differentiates into effector CTLs and memory CD8+ T cells with each successive cell division. According to this model, it is essential that each daughter cell be stimulated with antigen, otherwise CD8+ T cell division, and possibly differentiation, would be halted upon antigen removal. (b) Naïve CD8+ T cells are developmentally programmed to divide at least seven to ten times and to differentiate into effector CTLs and long-lived functional memory CD8+ T cells. Optimal antigenic stimulation of the parental cell triggers this developmental program and the CD8+ T cells become committed to proliferation and differentiation. Further antigenic stimulation of the daughter cells may increase the number of times the activated CD8+ T cells divide, but it is unnecessary for this developmental program to progress.

programme de différenciation



### **Different T Cell Receptor Signals Determine CD8<sup>+</sup> Memory Versus Effector Development**

Emma Teixeiro,<sup>1,2</sup>† Mark A. Daniels,<sup>1,2</sup>\* Sara E. Hamilton,<sup>3</sup>\* Adam G. Schrum,<sup>1,3</sup> Rafael Bragado,<sup>4</sup> Stephen C. Jameson,<sup>3</sup> Ed Palmer<sup>1</sup>†

23 JANUARY 2009 VOL 323 SCIENCE

We generated OT-1 TCR transgenic mice expressing a point mutation in the βTMD, where the most carboxyterminal tyrosine residue of the CART motif was replaced by a leucine (CART15 YL). TCR expression on mutant T cells was slightly decreased, but the mutant TCR-CD3 complex composition was unaltered . T cell maturation and homeostasis in 6TMD mutant mice (6TMDmut) were normal . The OT-1 and βTMDmut OT-1 TCRs recognize the ovalbumin peptide 257 to 264 (OVAp) bound to H-2Kb.

Using a mutant TCR transgenic model, we found that point mutations in the TCR ß transmembrane domain (βTMD) impair the development and function of CD8\* memory T cells without affecting primary effector T cell responses. Mutant T cells are deficient in polarizing the TCR and in organizing the nuclear factor B signal at the immunological synapse. Thus, effector and memory states of CD8<sup>+</sup> T cells are separable fates, determined by differential TCR signaling.

>> Importance of the TCR in regulating the NF-B signal required for memory development. We show here that effector and memory programming can be dissociated by the induction of a different arrangement of TCR signals in CD8+T cells







# mTOR regulates memory CD8 T cell differentiation

mTOR regulates memory CD8 T-cell differentiation.

Araki K & Ahmed R.

Nature. 2009 Jul



TCR >> mTOR >> Metabolism >> Memory differenciation





# Model of SLEC and MPEC development during acute viral infection.



Naive CD8 T cells are IL-7R<sup>hi</sup>, CD122<sup>lo</sup> (IL-2/15β), KLRG1<sup>neg</sup> and T-bet<sup>neg</sup> and are IL-7 dependent. Early during infection, most effector CD8 T cells become CD122<sup>hi</sup> and downregulate IL-7R to an intermediate-to-low level, but expression of T-bet and KLRG1 is set depending on their exposure to inflammatory cytokines (e.g. IL-12). Effector CD8 T cells that are exposed to lower levels of inflammation express less T-bet (light blue cells) and begin to upregulate IL-7R to become KLRG1<sup>lo</sup> IL-7R<sup>hi</sup> MPECs (turquoise cells). Effector CD8 T cells that encounter higher levels of inflammatory cytokines express relatively more T-bet and KLRG1 (dark blue cells), stably repress IL-7R and consequentially become KLRG1<sup>hi</sup> IL-7R<sup>lo</sup> SLECs. SLECs become IL-15 dependent, however, IL-15 alone cannot support their long-term persistence or homeostatic turnover and they decline over time. In contrast, MPECs remain dually responsive to IL-7 and IL-15 and preferentially develop into long-lived memory CD8 T cells that can self-renew.



# Conclusions

## • Paramètres de l'interaction TCR/CMH-Ag

- Affinité
- Avidité
- Temps contact
- Flexibilité du CMH-Ag
- Molécules adaptatrices / costimulation
- Déterminent
  - Activation lymphocytaire
  - Différenciation lymphocytaire



